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African Americans (AAs) have worse COVID-19-related outcomes
than Caucasians and Asians, a disparity currently attributed to poten-
tial social and economic factors. In this commentary, we endeavor to
examine important race-related differences in intrinsic thromboge-
nicity as another significant contributing factor and propose objective
hemostasis assessments to address racial disparities in COVID-19
outcomes.
A prothrombotic state plays a central role in the prognosis of
patients with COVID-19 with increased venous and arterial clotting
commonly described. Severe COVID-19 is associated with high D-
dimer, fibrinogen, and von Willebrand factor levels, and various lev-
els have been reported to predict dosing strategies, mortality, and
potential benefit from anticoagulation. A D-dimer >2600 ng/mL pre-
dicted venous thromboembolism (VTE) (area under the curve 0.760,
95% CI, 0.6610.858; p 0.0001, sensitivity 89.7%, and specificity
59.5%) among American ICU patients[1]. Also, elevated acute phase
reactants (C-reactive protein, fibrinogen, ferritin), and proinflamma-
tory cytokines (tumor necrosis factor -a and interleukins-1 and 6)
are COVID-19 hallmarks.
Racial disparities in thrombotic risk have been widely described in
the pre-COVID-19 era. AAs have higher VTE rates than Caucasians,
whereas Caucasians have higher rates than Asians/Pacific Islanders
[2]. African Americans with coronary artery disease (CAD) have
poorer cardiovascular outcomes, particularly death, than Caucasians
and Asians. The highest ischemic event rate after electiveE-mail address: Pgurbel@lifebridgehealth.org (P.A. Gurbel).
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women. This group also had the highest platelet-fibrin clot strength
as measured by thromboelastography, a marker independently pre-
dictive of ischemic events [3]. AA women had higher thrombin-
induced platelet-fibrin clot strength than Caucasians and race was an
independent predictor of high thrombin-induced platelet-fibrin clot
strength by multivariate analysis in another CAD study [4]. Throm-
boelastography in age- and sex-matched East Asians and Caucasians
(n-249 each) with stable CAD demonstrated delayed initiation of clot
formation, lower clot strength, and greater clot lysis in the former
race [5]. The disconnect between heightened platelet reactivity and
and lower post-PCI ischemic event rates, particularly stent thrombo-
sis, and higher bleeding in East Asians (a phenomenon called the
"East Asian Paradox"), further supports greater endogenous antith-
rombosis in East Asians [5].
Thrombotic outcome disparities have been attributed to specific
hemostasis factors
(Table 1). Caucasians more often have prothrombotic factor V and
prothrombin genetic mutations than Asians. AAs have the highest
factor VIII, plasmin-antiplasmin complex, and von Willebrand factor
levels versus intermediate levels in Caucasians and Hispanics and the
lowest levels in Asians (Table 1). D-dimer is highest in AAs and lowest
in Asians. Additionally, endothelial dysfunction is observed more
often in AAs than Caucasians, and disparate regulation of the Gq
pathway after protease-activated receptor-4 (PAR-4) stimulation
associated with greater platelet activation has been reported
(Table 1).
Caucasians also have higher CRP than Asians. After adjusting for
age, socioeconomic status, BMI, and other risk factors, AA race was
associated with increased CRP, and fibrinogen was higher in AAs than
Caucasians despite demographic adjustments (Table 1). The totality
of evidence supports that AAs have the most elevated inflammation
and thrombosis biomarkers, followed by Caucasians (especially of
European descent) and then Asians. The prothrombotic stimulus
induced by COVID-19 combined with inherent greater thromboge-
nicity likely contributes to the disparity in clinical outcomes amongr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Table 1
Race -related differences in intrinsic thrombogenicity and inflammation.
Factors Race/Ethnicity effect Interpretation
Factor V Leiden and G20210A mutationa,b Caucasians >> Asians Prothrombotic
Fibrinogen, factor VII, factor VIII, Plasmin-antiplasmin complex and VWF levelsc,d African Americans > Caucasians > Asians Prothrombotic
D-dimer levelsd,e African Americans > Caucasians > Asians Prothrombotic
Efficient coagulation inactivation by APC or enhanced fibrinolysisf Asians > Caucasians Fibrinolytic
Longer occlusion time on Global Thrombosis Testg Japanese >Westerners Delayed clot initiation
Prolonged time of initiation of clot formation; lower level of clot strength;
increased activity of clot lysish
East Asians > Caucasians Delayed clot initiation; Fibrinolytic
High on treatment platelet reactivity to clopidogrel; Increased prevalence of
CYP2C19£2 allele carrier statusi
African Americans > Caucasians Prothrombotic
High maximum platelet-fibrin clot strengthj African Americans > Caucasians Prothrombotic
Differential regulation of Gq pathway after PAR-4 stimulationk,l Blacks >Whites Prothrombotic
CRP elevationm,n African Americans > Hispanic > Caucasians > Asians Proinflammatory
VWF=vonWillebrand Factor; APC = Activated Protein C; CRP=C-reactive protein.
a Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet 1997;73:3346.
b Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA
1997;277:13057.
c Iso H, Folsom AR, Wu KK, et al. Hemostatic variables in Japanese and Caucasian men. Plasma fibrinogen, factor VIIc, factor VIIIc, and von Willebrand factor and their relations to
cardiovascular disease risk factors. Am J Epidemiol 1989;130:92534.
d Lutsey PL, Cushman M, Steffen LM, et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost 2006;4:262935.
e Weng LC, Tang W, Rich SS, et al. A genetic association study of D-dimer levels with 50 K SNPs from a candidate gene chip in four ethnic groups. Thromb Res 2014;134:4627.
f White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I48.
g Gorog DA, Yamamoto J, Saraf S, et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to
the "Japanese paradox". Int J Cardiol 2011;152:438.
h Jeong YH, Kevin B, Ahn JH, et al. Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a
COMPARE-RACE analysis. J Thromb Thrombolysis 2020 Aug 27. doi: 10.1007/s1123902002,2402.
i Pendyala LK, Torguson R, Loh JP, et al. Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention. Am Heart J
2013;166:26672.
j Lev EI, Bliden KP, Jeong YH, et al. Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc 2014;3:e001167.
k Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq sig-
naling axis. Arterioscler Thromb Vasc Biol 2014;34:264450.
l Edelstein LC, Simon LM, Lindsay CR, et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 2014;124:34508.
m Gijsberts CM, den Ruijter HM, Asselbergs FW, Chan MY, de Kleijn DP, Hoefer IE. Biomarkers of Coronary Artery Disease Differ Between Asians and Caucasians in the General
Population. Glob Heart 2015;10:30111 e11.
n Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, et al. Ethnic differences in C-reactive protein concentrations. Clin Chem 2008;54:102737.
2 R. Chaudhary et al. / EClinicalMedicine 2930 (2020) 100647racial groups. The preliminary results confirming the hypothesis
were recently reported by Zakeri et al.[6].
Currently, D-dimer is the most widely reported biomarker associ-
ated with COVID-19 severity and outcomes, with an escalation of
antithrombotic therapy proposed in patients with very high levels
[7,8]. However, there are several limitations of this biomarker to
monitor thrombogenicity during COVID-19. Despite evidence of ele-
vated D-dimer in patients with severe COVID-19, VTE was not evi-
dent in the majority. D-dimer, an acute phase reactant with low
specificity in the critically ill with conditions associated with fibrin
formation, is generated during fibrinolysis and reflects later stage
clot formation and hemostatic processes. There is also considerable
variation in D-dimer measurements and the reported units that has
made pooling of the studies for interpretation unreliable. About 2 -
3% of plasma fibrinogen is physiologically converted to crosslinked
fibrin and then degraded to D-dimer [9]. Thus, elevated levels of
fibrinogen in COVID-19 patients, especially among AAs, likely con-
tribute to higher D-dimer values without necessarily an associated
increase in fibrinolytic activity. Hence, even if the fibrinolytic sys-
tem is impaired, D-dimer values may be high. Finally, D-dimer does
not provide quantitative information on platelet function, thrombin
generation, and the kinetics of clot formation.
Some of these limitations can be addressed by global hemostasis
assays such as thromboelastography or rotational thromboelastome-
try. Whereas high D-dimer in COVID-19 may be associated with a
prothrombotic state, a hypofibrinolytic state, or both, viscoelastic
measurements of clot provide greater insight into the dynamics of
coagulation, platelet function and fibrinolysis. Viscoelastic measure-
ments can quantitate the response to both anticoagulant and anti-
platelet therapy [10]. Thromboelastography is a whole blood ex vivo
assay that provides viscoelastic measurements of the evolving clot
from the time of initial platelet-fibrin clot formation to clotstrengthening to clot lysis. It can be used to assess platelet function
and coagulation, the response to antiplatelet and anticoagulant
agents, and to quantify fibrinolysis. Among patients with COVID-19,
determination of thrombogenicity phenotype and response to antith-
rombotic agents can help to personalize the antithrombotic regimen
[10]. In an ongoing study, “The Evaluation of Hemostasis by Throm-
boelastography, Platelet Function Testing, and Biomarker Analysis in
Hospitalized COVID-19 Patients (TARGET-COVID Study)”
(NCT04493307) the influence of the early detection of hypercoagula-
bility on COVID-19 outcomes is being investigated.
Racial disparities in the outcomes of COVID-19 are surely influ-
enced by important social and economic factors. However, differen-
ces in mortality and thromboembolic event occurrences in COVID-19
may also be, in part, explained by important, but comparatively
unrecognized, race-related disparities in intrinsic thrombogenicity.
We hypothesize that a patient’s hemostatic blueprint determines
clinical outcomes in COVID-19 and that early viscoelastic analysis of
clot may facilitate future efforts to personalize antithrombotic ther-
apy [10]. Such personalization holds the promise of mitigating the
relationship of race to COVID-19 related outcomes.
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